High impact information on SLC16A6

• It is probable that MCT6 is involved in the disposition of various drugs, including bumetanide [1].
• Four loop diuretics, i.e., furosemide, piretanide, azosemide, and torasemide, thiazides, probenecid, glibenclamide, and nateglinide inhibited the MCT6-mediated uptake of [3H]bumetanide [1].
• Furthermore, MCT6 transported various drugs such as probenecid and nateglinide [1].
• These results suggest that the substrate specificity of MCT6 is distinct from those of other MCTs [1].
• Human monocarboxylate transporter 6 (MCT6) has recently been isolated, and its tissue distribution has been established at the mRNA level, but its functional properties remain unknown [1].

Anatomical context of SLC16A6

• When expressed in Xenopus laevis oocytes, MCT6 transported [3H]bumetanide in a pH- and membrane potential-sensitive but not proton gradient-dependent manner, with the K(t) value of 84 microM [1].

Associations of SLC16A6 with chemical compounds

• In contrast, short-chain carboxylic acids, such as L-lactic acid and succinic acid did not inhibit the MCT6-mediated uptake of bumetanide [1].
• In addition, MCT6 and -8 were also prominently expressed in this tissue, although it is known that MCT8 does not transport aromatic amino acids or lactate [2].

References